Specific Objective 5

Deployment: accelerating best use of technologies

About this programme

About the programme

 

Specific Objective 5 – Deployment and Accelerating the Best Use of Technologies promotes the roll-out and best use of digital capacities, prioritising areas such as the support of SMEs and public authorities in their digital transformation.

Under the 2025-2027 main work programme, the following aspects will be covered:

  • European Digital Government Ecosystem including the EU Digital Identity Wallet architecture and its European Trust Infrastructure and the Once Only Technical System
  • Interoperable Europe, supporting the transition to a data-driven, user-centric and AI-enabled digital government
  • Justice and consumers, promoting the transition towards digitalisation of services and exchange of documents
  • Confidence in digital transformation, focusing on safer internet usage for kids and the fight against disinformation.
Click to read more 
Hide text 

Your NCP contact for this programme

Image of Marie Timmermann

Marie Timmermann

marie.timmermann@fwo.be

+32 2 550 15 59

Your PC contact for this programme

Find the contact info on the site of WEWIS

The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.

The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.

Latest news

Related links

Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.

Documents

Documents contain additional information related to this programme, and are similar to related links.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.